June 26, 2023Improving the transparency of clinical trials in the EUOn 22 and 23 June 2023, EPHA attended the kick-off workshop of the multistakeholder platform...ReportsHealthcare DeliveryEurope and Health
June 1, 2023EPHA Newsletter | Exploring elements of the EU’s pharmaceutical legislationDeveloped in 1965, the first EU pharmaceutical legislation was a response to the tragic consequences...NewslettersHealthcare DeliveryAccess to Medicines
May 31, 2023Will transparency of R&D costs lead to more affordable medicines?Without clear knowledge of pharmaceutical R&D costs, it is virtually impossible for regulators to design...OpinionHealthcare DeliveryAccess to Medicines
April 12, 2023Why should one care about the new EU pharma law?Have you ever been to the pharmacy and couldn’t find the medicine you were looking...PodcastsHealthcare DeliveryPolitics and HealthAccess to Medicines
February 10, 2023Transferable exclusivity voucher: a flawed incentive to stimulate antibiotic innovationThe transferable exclusivity voucher is a costly, complex and untested incentive for new antibiotics. It...Position & Policy PapersHealthcare DeliveryAccess to Medicines
